Navigation Links
Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients
Date:4/2/2011

aid (8%). Almost a third (31%) of the Medicare CDI hospital stays (initial or re-hospitalizations) included services in the intensive care unit (ICU) with an average length of stay in the ICU of 8.2 days. Almost two-thirds (62%) of the Medicare CDI hospital stays (initial or re-hospitalizations) included services in semi-private rooms with an average length of stay in semi-private rooms of 9.5 days.  We believe the study highlights the substantial economic burden of both acute and recurrent CDI. The dreaded outcomes – recurrence and death – are seen more commonly in the elderly and those with serious underlying diseases.

For a complete list of abstracts, please visit the Resources page on our website: www.optimerpharma.com

About Fidaxomicin

Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). In two Phase 3 trials for the treatment of CDI, fidaxomicin was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI.  Fidaxomicin also demonstrated statistically significant reduction in recurrences and an increase in global cure rate, defined as cure without recurrence. Importantly,  fidaxomicin reduced the risk of recurrence by 47% compared to vancomycin. The New England Journal of Medicine has published results from the first Phase 3 trial in an article titled, "Fidaxomicin versus Vancomycin for Clostridium difficile Infection," which appeared in the February 3, 2011 issue.

About Clostridium difficile Infection (CDI)

Clostridium difficile infection (CDI), commonly referred to as "C. difficile" or "c-diff", has become a significant medical problem in hospitals, long-term care facilities, and in the community and is estimated to afflict more than 700,000 people each yea
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... 2011 Omnicell, Inc . (NASDAQ: ... and supply management solutions and analytics software for ... Hospital (RVH) selected Omnicell G4 solutions to ... Omnicell,s hallmark flexibility and functionality, RVH became the ...
... 26, 2011 PolyGel, the manufacturer of Orthopedic, ... long term exclusive distribution agreement with China National ... in Beijing, China, Sinopharm Foreign Trade is a ... (SINOPHARM Group). (Photo:   http://photos.prnewswire.com/prnh/20110726/NY40954 ...
Cached Medicine Technology:Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 2Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 3Royal Victoria Hospital Selects Omnicell to Improve Patient Safety with Automated Medication Management 4PolyGel Signs Long Term Exclusive Agreement With China's Largest Distributor of Healthcare Products 2
(Date:4/18/2014)... Harvard neuroscientists have made a discovery that turns 160 ... electrical insulating material long known to be essential for ... nerve cells, is not as ubiquitous as thought, according ... of the Harvard Stem Cell Institute (HSCI) and the ... collaboration with Professor Jeff Lichtman, of Harvard,s Department of ...
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... This news release is available in French . ... breakthrough could revolutionize surgical practice and regenerative medicine. A ... Molle et Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur ... and Paris 13), has just demonstrated that the principle ... used in vivo to repair soft-tissue organs and tissues. ...
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... at Jefferson have found a mechanism by which a ... makes breast cancer more aggressive. Publishing in the ... prolactin, a pituitary hormone that normally stimulates breast development ... oncogene called BCL6. The BCL6 protein has previously been ...
... Predictive, Preventive and Personalised Medicine have founded, as the ... Creating a reliable scientific platform for the optimal combination ... laboratory medicine, the EPMA Journal will highlight ... and personalised medicine. The EPMA Journal ...
... , CARROLLTON, Texas , Feb. ... (AAUCM) has begun a sponsorship of the A-Claim™ medical payment ... , A-Claim ( www.A-Claim.com ) is a proprietary medical payment ... Carrollton, Texas , that is changing the way physicians, hospitals ...
... Nixon declared a "War on Cancer," the disease still claims ... expenditure of $5 billion by the U.S. government on research ... made since Nixon,s call to action in 1971, cancer research ... which is only increasing as scientists discover new drugs and ...
... ... As Strauss Radio Strategies continues to grow and expand, it has ... signing onto the GSA Schedule - the federal government procurement system. Government ... base and the addition to the GSA schedule will greatly facilitate the ...
... ... , ... February 3, 2010 -- Governance, Risk and Compliance (GRC) leader MetricStream ... over 2008 combined with record profits. MetricStream’s growth was fueled by companies prioritizing their need ...
Cached Medicine News:Health News:Springer publishes new journal in predictive, preventive and personalized medicine 2Health News:Urgent Care Providers Tout Benefits of A-Claim Medical Payment Solution 2Health News:Urgent Care Providers Tout Benefits of A-Claim Medical Payment Solution 3Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 2Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 3Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 4Health News:Developing a cyberinfrastructure for comparative effectiveness in cancer research 5Health News:Strauss Radio Strategies - The Nation's Leading Radio Media Relations Firm - Expands Government Business with Award on GSA Schedule 2Health News:Strauss Radio Strategies - The Nation's Leading Radio Media Relations Firm - Expands Government Business with Award on GSA Schedule 3Health News:MetricStream Achieves Record Revenue Growth in 2009 with Global Customer Adoption of its Enterprise GRC Platform and Solutions 2Health News:MetricStream Achieves Record Revenue Growth in 2009 with Global Customer Adoption of its Enterprise GRC Platform and Solutions 3Health News:MetricStream Achieves Record Revenue Growth in 2009 with Global Customer Adoption of its Enterprise GRC Platform and Solutions 4
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
Shandon Paraffin Block Cabinet...
Medicine Products: